Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data - Schreiber, S; Colombel, J F; Bloomfield, R (Am J Gastroenterol, 2010)
et al.